Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Onvatilimab, an antibody targeting VSIR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imaprelimab, an antibody targeting MCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gimsilumab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cofetuzumab, an antibody targeting PTK7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abrezekimab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vibecotamab, an antibody targeting IL3RA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tidutamab, an antibody targeting SSTR2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tamrintamab, an antibody targeting DPEP3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tabituximab, an antibody targeting FZD10.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rolinsatamab, an antibody targeting PRLR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elipovimab, an antibody targeting HIV-1 gp120.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atoltivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.